Luvadaxistat
Overview of the drug Luvadaxistat
Luvadaxistat is a pharmaceutical compound that functions as a reversible inhibitor of the enzyme D-amino acid oxidase (DAAO). It is primarily being investigated for its potential therapeutic effects in the treatment of schizophrenia and other neuropsychiatric disorders.
Mechanism of Action[edit]
Luvadaxistat works by inhibiting the activity of D-amino acid oxidase, an enzyme responsible for the degradation of D-serine, a co-agonist of the NMDA receptor. By inhibiting DAAO, luvadaxistat increases the levels of D-serine in the brain, which in turn enhances NMDA receptor function. This mechanism is thought to be beneficial in conditions like schizophrenia, where NMDA receptor hypofunction is implicated.
Clinical Development[edit]
Luvadaxistat is currently undergoing clinical trials to evaluate its efficacy and safety in the treatment of schizophrenia. The drug is being developed by Takeda Pharmaceuticals.
Phase I Trials[edit]
Initial phase I trials focused on assessing the safety, tolerability, and pharmacokinetics of luvadaxistat in healthy volunteers. These studies helped establish the appropriate dosing regimen for subsequent trials.
Phase II Trials[edit]
Phase II trials are designed to evaluate the efficacy of luvadaxistat in patients with schizophrenia. These studies aim to determine whether the drug can improve symptoms such as cognitive deficits and negative symptoms, which are often inadequately addressed by current antipsychotic medications.
Potential Benefits[edit]
The potential benefits of luvadaxistat in treating schizophrenia include improved cognitive function and reduction in negative symptoms. By enhancing NMDA receptor activity, luvadaxistat may address some of the underlying pathophysiological mechanisms of schizophrenia that are not targeted by traditional antipsychotics.
Side Effects[edit]
As with any pharmacological treatment, luvadaxistat may have side effects. Commonly reported side effects in clinical trials include headache, nausea, and dizziness. The safety profile of luvadaxistat continues to be evaluated in ongoing studies.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
